Showing 6161-6170 of 19385 results for "".
FDA Approves Eli Lilly’s AD Drug Ebglyss (Lebrikizumab)
https://reachmd.com/series/dermwire-tv/fda-approves-eli-lillys-ad-drug-ebglyss-lebrikizumab/28645/In this week's DermwireTV, Andrew F. Alexis, MD, Professor of Clinical Dermatology at Weill Cornell Medical College, discusses the newly approved AD drug lebrikizumab; LEO Pharma announces two major regulatory milestones for its chronic hand eczema (CHE) treatment; and the CMO of Arcutis BioteherapuPeyronie's Disease: Evaluation and Diagnosis
https://reachmd.com/programs/clinicians-roundtable/peyronies-disease-evaluation-and-diagnosis/2656/The management of Peyronie's disease (PyD) presents several challenges to the clinician. Despite progress in the understanding of PyD on several fronts, it remains a physically and psychologically devastating condition for the affected patient and his partner. Anthony Bella MD, an international expeThe Use of Electroconvulsive Therapy Today
https://reachmd.com/programs/clinicians-roundtable/the-use-of-electroconvulsive-therapy-today/2590/Historian Doctor Edward Shorter of the University of Toronto and author of "Shock Therapy: The History of Electroconvulsive Treatment in Mental Illness" discusses the use of electroconvulsive therapy today.The Birth of a Drug: Regulatory Factors in Vitamin and Herbal Therapy Claims
https://reachmd.com/programs/clinicians-roundtable/the-birth-of-a-drug-regulatory-factors-vitamin-herbal-therapy-claims/1325/Dr. Michael Greenberg talks to Katie MacFarlane, President and CEO of Xintria Pharmaceutical Corporation about the FDA and its involvement in the birth of a new medication and the different rules that vitamins and herbal medications have regarding therapeutic claims.Sexual Activity After Genital Tract Cancer
https://reachmd.com/programs/clinicians-roundtable/sexual-activity-after-genital-tract-cancer/1466/As the Baby Boomers approach retirement, many aspects of their lives are changing. For longterm cancer survivors, changes in sexual activity are often overlooked. Dr. Shira Johnson interviews Dr. Stacy Tessler Lindau for a look at longterm sexual activity after genital tract cancer.Child Abuse: Detection and Reporting
https://reachmd.com/programs/clinicians-roundtable/child-abuse-detection-and-reporting/1652/Dr Shira Johnson interviews Dr. Walter Lambert, who has been the medical director of the Child Protection Team at University of Miami/Jackson Memorial Hospital since 1988. He has been honored by the Florida Bar Association for his many years of work as Protector of the Innocents.Octane Aesthetics Tech Forum: Combination Treatment Strategies May Evolve for Patients Using GLP-1 RAs
https://reachmd.com/conferences/octane-atf-2026/octane-aesthetics-tech-forum-combination-treatment-strategies-may-evolve-for-patients-using-glp-1-ras/54706/Arash Moradzadeh, MD, founder of AM Facial Plastics, shares his perspective on aesthetic treatments and trends poised to disrupt the market in 2026. He discusses the expanding role of GLP-1 RA medications in aesthetics, including what’s on the horizon for these therapies.Making the Right Choices for Patients with Ulcerative Colitis
https://reachmd.com/programs/gi-insights/right-choices-ulcerative-colitis-treatment/39216/Ulcerative colitis treatment continues to evolve with a growing range of targeted therapies, from S1P modulators to JAK inhibitors. Joining Dr. Peter Buch to discuss how clinicians can personalize care based on disease severity, safety profiles, and patient response is Dr. David Hudesman. He's a ProDiagnosing LCNEC of the Lung: Challenges and Strategies
https://reachmd.com/programs/project-oncology/diagnosing-lcnec-of-the-lung-challenges-and-strategies/36457/Large cell neuroendocrine carcinoma (LCNEC) of the lung can pose significant diagnostic challenges due to its overlapping features with other lung cancers. Explore the pathologic hallmarks, immunohistochemical markers, and emerging molecular insights that are shaping more accurate diagnosis and targBiomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
https://reachmd.com/programs/project-oncology/biomarker-breakthroughs-a-look-at-whats-next-for-kidney-cancer-care/35923/Due to the heterogeneous nature of kidney cancer, it can be challenging to identify reliable biomarkers, but integrated models that combine genetic, histologic, and blood-based data are helping to pave the way toward more predictive and clinically useful tools. Joining Ryan Quigley to share insights